Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Carkaci S, Adrada BE, Rohren E, Wei W, Quraishi MA, Mawlawi O, Buchholz TA, Yang W.

Acad Radiol. 2012 May;19(5):535-41. doi: 10.1016/j.acra.2012.01.001. Epub 2012 Feb 1.

2.

FDG-PET for axillary lymph node staging in primary breast cancer.

Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S97-102. Epub 2004 May 5. Review.

PMID:
15133635
3.

PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.

Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I Figuls M.

Cochrane Database Syst Rev. 2014 Nov 13;(11):CD009519. doi: 10.1002/14651858.CD009519.pub2. Review.

PMID:
25393718
4.

Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.

Guan ZW, Xu BX, Wang RM, Sun L, Tian JH.

Hell J Nucl Med. 2013 May-Aug;16(2):97-102. doi: 10.1967/s002449910084. Epub 2013 May 20. Review.

5.

Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature.

Yamashita H, Kubota K, Takahashi Y, Minamimoto R, Morooka M, Kaneko H, Kano T, Mimori A.

Mod Rheumatol. 2014 Jul;24(4):645-50. doi: 10.3109/14397595.2013.850998. Epub 2013 Nov 4. Review.

PMID:
24252024
6.

Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance.

Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, Scott JA, Kalra MK.

Radiology. 2011 Apr;259(1):117-26. doi: 10.1148/radiol.11100569. Epub 2011 Feb 17. Review.

PMID:
21330566
7.

Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.

Ziai P, Hayeri MR, Salei A, Salavati A, Houshmand S, Alavi A, Teytelboym OM.

Radiographics. 2016 Mar-Apr;36(2):481-96. doi: 10.1148/rg.2016150102. Review.

PMID:
26963458
8.

[FDG-PET and endometrial cancer].

Kolesnikov-Gauthier H, Carpentier P.

Bull Cancer. 2012 Jan;99(1):21-8. doi: 10.1684/bdc.2011.1514. Review. French.

9.

Dual-time point 18F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations.

Parghane RV, Basu S.

Semin Nucl Med. 2017 Jul;47(4):373-391. doi: 10.1053/j.semnuclmed.2017.02.009. Epub 2017 Apr 19. Review.

PMID:
28583277
10.

Potential value of dual-time-point ¹⁸F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: a systematic review and meta-analysis.

Lin YY, Chen JH, Ding HJ, Liang JA, Yeh JJ, Kao CH.

Nucl Med Commun. 2012 Oct;33(10):1011-8. doi: 10.1097/MNM.0b013e32835710d6. Review.

PMID:
22825038
11.

Role of sonography for the locoregional staging of breast cancer.

Lane DL, Adeyefa MM, Yang WT.

AJR Am J Roentgenol. 2014 Nov;203(5):1132-41. doi: 10.2214/AJR.13.12311. Review.

PMID:
25341155

Supplemental Content

Support Center